An antitrust suit filed on behalf of a class of end payors alleges Celgene Corp. took steps to prevent the approval of generic versions of its cancer drugs Thalomid and Revlimid.
Celgene charges up to $500 per capsule for the drugs, and has taken in $17.1 billion selling them from 2009 to 2013, the suit says. The company has unlawfully perpetuated a monopoly by interfering with efforts to develop generic versions, according to the suit. The plaintiff, the city of Providence, Rhode Island, brought the suit on behalf of users and end payors of the drugs.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
